+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Upper Respiratory Tract Infection Treatment Market 2020-2024

  • PDF Icon

    Report

  • 120 Pages
  • May 2020
  • Region: Global
  • TechNavio
  • ID: 5025028
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Global Upper Respiratory Tract Infection Treatment Market 2020-2024

The upper respiratory tract infection treatment market is poised to grow by $ 1.79 billion during 2020-2024 progressing at a CAGR of 3% during the forecast period. The reports on upper respiratory tract infection treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the rising incidence and prevalence of upper respiratory tract infections, favourable drug pipeline, and rising demand for over-the-counter drugs. In addition, rising incidence and prevalence of upper respiratory tract infections is anticipated to boost the growth of the market as well.

The upper respiratory tract infection treatment market analysis includes type segment and geographic landscapes.

The upper respiratory tract infection treatment market is segmented as below:

By Type
  • Antibiotics
  • NSAIDs and nasal decongestants
  • others

By Geographic Landscapes
  • North America
  • Europe
  • Asia
  • ROW

This study identifies the increasing R&D on upper respiratory tract infection treatment as one of the prime reasons driving the upper respiratory tract infection treatment market growth during the next few years. Also, emergence of biologics, and development of drug delivery devices to treat upper respiratory tract infections will lead to sizable demand in the market.

The upper respiratory tract infection treatment market covers the following areas:
  • Upper respiratory tract infection treatment market sizing
  • Upper respiratory tract infection treatment market forecast
  • Upper respiratory tract infection treatment market industry analysis

This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading upper respiratory tract infection treatment market vendors that include AstraZeneca Plc, CSL Ltd., GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi, and Teva Pharmaceutical Industries Ltd.. Also, the upper respiratory tract infection treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

This study presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary.

The market research report provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary
  • Market Overview

Market Landscape
  • Market ecosystem
  • Value chain analysis

Market Sizing
  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis
  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Type
  • Market segments
  • Comparison by Type
  • Antibiotics - Market size and forecast 2019-2024
  • NSAIDs and nasal decongestants - Market size and forecast 2019-2024
  • Others - Market size and forecast 2019-2024
  • Market opportunity by Type

Customer landscape
Geographic Landscape
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Volume driver – demand led growth
  • Market challenges
  • Market trends

Vendor Landscape
  • Vendor landscape
  • Landscape disruption
  • Competitive scenario

Vendor Analysis
  • Vendors covered
  • Market positioning of vendors
  • AstraZeneca Plc
  • CSL Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline Plc
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.

Appendix
  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

List of Exhibits
1: Key Finding 1
2: Key Finding 2
3: Key Finding 3
4: Key Finding 5
5: Key Finding 6
6: Key Finding 7
7: Key Finding 8
8: Parent market
9: Market characteristics
10: Offerings of vendors included in the market definition
11: Market segments
12: Global - Market size and forecast 2019 - 2024 ($ billion)
13: Global market: Year-over-year growth 2019 - 2024 (%)
14: Five forces analysis 2019 & 2024
15: Bargaining power of buyers
16: Bargaining power of suppliers
17: Threat of new entrants
18: Threat of substitutes
19: Threat of rivalry
20: Market condition - Five forces 2019
21: Type - Market share 2019-2024 (%)
22: Comparison by Type
23: Antibiotics - Market size and forecast 2019-2024 ($ billion)
24: Antibiotics - Year-over-year growth 2019-2024 (%)
25: NSAIDs and nasal decongestants - Market size and forecast 2019-2024 ($ billion)
26: NSAIDs and nasal decongestants - Year-over-year growth 2019-2024 (%)
27: Others - Market size and forecast 2019-2024 ($ billion)
28: Others - Year-over-year growth 2019-2024 (%)
29: Market opportunity by Type
30: Customer landscape
31: Market share by geography 2019-2024 (%)
32: Geographic comparison
33: North America - Market size and forecast 2019-2024 ($ billion)
34: North America - Year-over-year growth 2019-2024 (%)
35: Europe - Market size and forecast 2019-2024 ($ billion)
36: Europe - Year-over-year growth 2019-2024 (%)
37: Asia - Market size and forecast 2019-2024 ($ billion)
38: Asia - Year-over-year growth 2019-2024 (%)
39: ROW - Market size and forecast 2019-2024 ($ billion)
40: ROW - Year-over-year growth 2019-2024 (%)
41: Key leading countries
42: Market opportunity by geography ($ billion)
43: Impact of drivers and challenges
44: Vendor landscape
45: Landscape disruption
46: Industry risks
47: Vendors covered
48: Market positioning of vendors
49: AstraZeneca Plc - Overview
50: AstraZeneca Plc - Business segments
51: AstraZeneca Plc - Key offerings
52: AstraZeneca Plc - Key customers
53: AstraZeneca Plc - Segment focus
54: CSL Ltd. - Overview
55: CSL Ltd. - Business segments
56: CSL Ltd. - Key offerings
57: CSL Ltd. - Key customers
58: CSL Ltd. - Segment focus
59: GlaxoSmithKline Plc - Overview
60: GlaxoSmithKline Plc - Business segments
61: GlaxoSmithKline Plc - Key offerings
62: GlaxoSmithKline Plc - Key customers
63: GlaxoSmithKline Plc - Segment focus
64: Merck & Co. Inc. - Overview
65: Merck & Co. Inc. - Business segments
66: Merck & Co. Inc. - Key offerings
67: Merck & Co. Inc. - Key customers
68: Merck & Co. Inc. - Segment focus
69: Novartis AG - Overview
70: Novartis AG - Business segments
71: Novartis AG - Key offerings
72: Novartis AG - Key customers
73: Novartis AG - Segment focus
74: Pfizer Inc. - Overview
75: Pfizer Inc. - Business segments
76: Pfizer Inc. - Key offerings
77: Pfizer Inc. - Key customers
78: Pfizer Inc. - Segment focus
79: Regeneron Pharmaceuticals Inc. - Overview
80: Regeneron Pharmaceuticals Inc. - Business segments
81: Regeneron Pharmaceuticals Inc. - Key offerings
82: Regeneron Pharmaceuticals Inc. - Key customers
83: Regeneron Pharmaceuticals Inc. - Segment focus
84: Sanofi - Overview
85: Sanofi - Business segments
86: Sanofi - Key offerings
87: Sanofi - Key customers
88: Sanofi - Segment focus
89: Teva Pharmaceutical Industries Ltd. - Overview
90: Teva Pharmaceutical Industries Ltd. - Business segments
91: Teva Pharmaceutical Industries Ltd. - Key offerings
92: Teva Pharmaceutical Industries Ltd. - Key customers
93: Teva Pharmaceutical Industries Ltd. - Segment focus
94: Currency conversion rates for US$
95: Research Methodology
96: Validation techniques employed for market sizing
97: Information sources
98: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global upper respiratory tract infection treatment market: AstraZeneca Plc, CSL Ltd., GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi, and Teva Pharmaceutical Industries Ltd.

Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is increasing r&d on upper respiratory tract infection treatment."

According to the report, one of the major drivers for this market is the rising incidence and prevalence of upper respiratory tract infections.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AstraZeneca Plc
  • CSL Ltd.
  • GlaxoSmithKline Plc
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.